The United Kingdom and the United States have hammered out a key bilateral deal that will guarantee no duties on UK pharmaceutical shipments going into the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase expenditure on medicines through the NHS. This commitment ensures that tariffs on these crucial exports will stay at zero for a period of the next three years.
This development follows previous threats to hike import taxes on branded pharmaceutical imports, with figures discussed up to double the cost.
"This deal with the Britain reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to American-British medicine commerce," a release said.
Economic Impact
Drugs are one of the UK's biggest goods shipped to the US, which is easily the biggest buyer for large UK drugmakers.
Trade data reveal that in the 12 months prior to last September, the UK shipped drugs valued at £11.1bn to the US. This amount made up a significant portion of British export trade in that period.
"This agreement safeguards work, increases funding and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The pact entails several specific changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded twenty percent.
Broader Context
The deal comes amid a long-running row between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were heightened by arguments that American consumers were charged several times more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or abandoned, while substantial funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the last ten years.
